Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and treated with covalent Bruton tyrosine kinase inhibitors: A real-world study

Molecule: Zanubrutinib

BGB-3111-215 Trial

BGB-3111-215 (NCT04116437) is a Phase 2, multicenter, single-arm trial of zanubrutinib in patients with previously treated B-cell lymphoma intolerant of prior treatment with ibrutinib and/or acalabrutinib.

Reading
28 May 2025